Systemic delivery and preclinical evaluation of Au nanoparticle containing β-lapachone for radiosensitization

Journal of Controlled Release

Volumn 139, Issue 3, 2009, Pages 239-245

  Jeong, Seong Yun ^a   Park, Sung Jin ^a   Yoon, Sang Min ^b   Jung, Joohee ^a   Woo, Ha Na ^a   Yi, So Lyoung ^b   Song, Si Yeol ^b   Park, Heon Joo ^a,c   Kim, Chulhee ^a,d   Lee, Jin Seong ^a,b   Lee, Jung Shin ^a,b   Choi, Eun Kyung ^a,b  

^a Asan Medical Center   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Inha University School of Medicine   (South Korea)

^d Inha University   (South Korea)

Author keywords

Au; Delivery; Lapachone; Nanoparticle; Radiosensitization

Indexed keywords

ACTIVE TARGETING; ANTI-CANCER AGENTS; ANTI-EGFR; AU; AU NANOPARTICLE; CANCER CELLS; CELL LINES; CLINICAL APPLICATION; DELIVERY; GOLD NANOPARTICLE; HUMAN CANCER; HUMAN TUMORS; IN-VITRO; IN-VIVO; INTRAVENOUS INJECTIONS; LAPACHONE; NAD(P)H; NEW MODALITY; OXIDOREDUCTASES; RADIOSENSITIZATION; RADIOSENSITIZERS; SPECIFIC DISTRIBUTION; TUMOR CELLS;

ANTIBODIES; CELL CULTURE; CELL MEMBRANES; CYTOTOXICITY; ENZYMES; NANOPARTICLES; TUMORS;

GOLD;

BETA LAPACHONE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GOLD NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CANCER RADIOTHERAPY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; TUMOR;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG COMPOUNDING; DRUG EVALUATION, PRECLINICAL; GOLD; HUMANS; INJECTIONS, INTRAVENOUS; LUNG NEOPLASMS; METAL NANOPARTICLES; MICE; MICE, INBRED BALB C; MICE, NUDE; NAPHTHOQUINONES; RADIATION-SENSITIZING AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70349306262     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.07.007     Document Type: Article

References (32)

1. Jothy Basu K.S., Bahl A., Subramani V., Sharma D.N., Rath G.K., and Julka P.K. Normal tissue complication probability of fibrosis in radiotherapy of breast cancer: accelerated partial breast irradiation vs conventional external-beam radiotherapy. J. Cancer Res. Ther. 4 3 (2008) 126-130
2. Miller K.L., Shafman T.D., Anscher M.S., Zhou S.M., Clough R.W., Garst J.L., Crawford J., Rosenman J., Socinski M.A., Blackstock W., Sibley G.S., and Marks L.B. Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer?. Int. J. Radiat. Oncol. Biol. Phys. 61 1 (2005) 64-69
3. Valerie K., Yacoub A., Hagan M.P., Curiel D.T., Fisher P.B., Grant S., and Dent P. Radiation-induced cell signaling: inside-out and outside-in. Mol. Cancer Ther. 6 3 (2007) 789-801
4. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., and Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2 12 (2007) 751-760
5. Kohli E., Han H.Y., Zeman A.D., and Vinogradov S.V. Formulations of biodegradable Nanogel carriers with 5′-triphosphates of nucleoside analogs that display a reduced cytotoxicity and enhanced drug activity. J. Control. Release 121 1-2 (2007) 19-27
6. Jeong S.Y., Yi S.L., Lim S.K., Park S.J., Jung J., Woo H.N., Song S.Y., Kim J.S., Lee J.S., Park H.J., and Choi E.K. Enhancement of radiotherapeutic effectiveness by temperature-sensitive liposomal 1-methylxanthine. Int. J. Pharm. (2009)
7. Kopecek J. Smart and genetically engineered biomaterials and drug delivery systems. Eur. J. Pharm. Sci. 20 1 (2003) 1-16
8. Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2 5 (2003) 347-360
9. Pardee A.B., Li Y.Z., and Li C.J. Cancer therapy with beta-lapachone. Curr. Cancer Drug Targets 2 3 (2002) 227-242
10. Tagliarino C., Pink J.J., Dubyak G.R., Nieminen A.L., and Boothman D.A. Calcium is a key signaling molecule in beta-lapachone-mediated cell death. J. Biol. Chem. 276 22 (2001) 19150-19159
11. Don M.J., Chang Y.H., Chen K.K., Ho L.K., and Chau Y.P. Induction of CDK inhibitors (p21(WAF1) and p27(Kip1)) and Bak in the beta-lapachone-induced apoptosis of human prostate cancer cells. Mol. Pharmacol. 59 4 (2001) 784-794
12. Pink J.J., Planchon S.M., Tagliarino C., Varnes M.E., Siegel D., and Boothman D.A. NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. J. Biol. Chem. 275 8 (2000) 5416-5424
13. Li C.J., Li Y.Z., Pinto A.V., and Pardee A.B. Potent inhibition of tumor survival in vivo by beta-lapachone plus taxol: combining drugs imposes different artificial checkpoints. Proc. Natl. Acad. Sci. U. S. A. 96 23 (1999) 13369-13374
14. Kumi-Diaka J. Chemosensitivity of human prostate cancer cells PC3 and LNCaP to genistein isoflavone and beta-lapachone. Biol. Cell 94 1 (2002) 37-44
15. Boorstein R.J., and Pardee A.B. Beta-lapachone greatly enhances MMS lethality to human fibroblasts. Biochem. Biophys. Res. Commun. 118 3 (1984) 828-834
16. Park H.J., Choi E.K., Choi J., Ahn K.J., Kim E.J., Ji I.M., Kook Y.H., Ahn S.D., Williams B., Griffin R., Boothman D.A., Lee C.K., and Song C.W. Heat-induced up-regulation of NAD(P)H:quinone oxidoreductase potentiates anticancer effects of beta-lapachone. Clin. Cancer Res. 11 24 Pt 1 (2005) 8866-8871
17. Park H.J., Ahn K.J., Ahn S.D., Choi E., Lee S.W., Williams B., Kim E.J., Griffin R., Bey E.A., Bornmann W.G., Gao J., Boothman D.A., and Song C.W. Susceptibility of cancer cells to beta-lapachone is enhanced by ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys. 61 1 (2005) 212-219
18. Choi E.K., Terai K., Ji I.M., Kook Y.H., Park K.H., Oh E.T., Griffin R.J., Lim B.U., Kim J.S., Lee D.S., Boothman D.A., Loren M., Song C.W., and Park H.J. Upregulation of NAD(P)H:quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells. Neoplasia 9 8 (2007) 634-642
19. Begleiter A., and Fourie J. Induction of NQO1 in cancer cells. Methods Enzymol. 382 (2004) 320-351
20. Ough M., Lewis A., Bey E.A., Gao J., Ritchie J.M., Bornmann W., Boothman D.A., Oberley L.W., and Cullen J.J. Efficacy of beta-lapachone in pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1. Cancer Biol. Ther. 4 1 (2005) 95-102
21. Nasongkla N., Wiedmann A.F., Bruening A., Beman M., Ray D., Bornmann W.G., Boothman D.A., and Gao J. Enhancement of solubility and bioavailability of beta-lapachone using cyclodextrin inclusion complexes. Pharm. Res. 20 10 (2003) 1626-1633
22. Connor E.E., Mwamuka J., Gole A., Murphy C.J., and Wyatt M.D. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small 1 3 (2005) 325-327
23. Han G., Ghosh P., and Rotello V.M. Functionalized gold nanoparticles for drug delivery. Nanomedicine 2 1 (2007) 113-123
24. Hong R., Han G., Fernandez J.M., Kim B.J., Forbes N.S., and Rotello V.M. Glutathione-mediated delivery and release using monolayer protected nanoparticle carriers. J. Am. Chem. Soc. 128 4 (2006) 1078-1079
25. Gibson J.D., Khanal B.P., and Zubarev E.R. Paclitaxel-functionalized gold nanoparticles. J. Am. Chem. Soc. 129 37 (2007) 11653-11661
26. Podsiadlo P., Sinani V.A., Bahng J.H., Kam N.W., Lee J., and Kotov N.A. Gold nanoparticles enhance the anti-leukemia action of a 6-mercaptopurine chemotherapeutic agent. Langmuir 24 2 (2008) 568-574
27. Park H.J., Lee S.H., Chung H., Rhee Y.H., Lim B.U., Ha S.W., Griffin R.J., Lee H.S., Song C.W., and Choi E.K. Influence of environmental pH on G2-phase arrest caused by ionizing radiation. Radiat. Res. 159 1 (2003) 86-93
28. Choi E.K., Roberts K.P., Griffin R.J., Han T., Park H.J., and Song C.W. Effect of pH on radiation-induced p53 expression. Int. J. Radiat. Oncol. Biol. Phys. 60 4 (2004) 1264-1271
29. Cho K., Wang X., Nie S., Chen Z.G., and Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 14 5 (2008) 1310-1316
30. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41 (2001) 189-207
31. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2 10 (2002) 750-763
32. Daniel M.C., and Astruc D. Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. Chem. Rev. 104 1 (2004) 293-346